Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2015 - 2026)

Insight Molecular Diagnostics has reported Accumulated Expenses for 12 years, with the latest figure at $3.3 million in Q1 2026.

• Quarterly Accumulated Expenses rose 72.96% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 72.96% YoY) and the FY2025 annual result came in at $939000.0, down 51.57% from the prior year.
• Accumulated Expenses improved to $3.3 million in Q1 2026 per IMDX's latest filing, from $939000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $4.1 million in Q3 2022 and troughed at $602000.0 in Q3 2025.
• A 5-year average of $2.0 million and a median of $1.8 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses plunged 57.66% in 2023, then jumped 72.96% in 2026.
• Over 5 years, Accumulated Expenses stood at $1.8 million in 2022, then declined by 6.89% to $1.6 million in 2023, then climbed by 17.59% to $1.9 million in 2024, then tumbled by 51.57% to $939000.0 in 2025, then soared by 254.95% to $3.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.3 million, $939000.0, and $602000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.